Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Net Cash Flow data on file, last reported at -$49.9 million in Q2 2026.

• Quarterly Net Cash Flow rose 31.92% year-over-year to -$49.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$208.4 million (up 13.91% YoY) and the FY2025 annual result came in at -$252.2 million, down 171.27% from the prior year.
• Net Cash Flow advanced to -$49.9 million in Q2 2026, from -$66.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $504.6 million in Q2 2024 to a low of -$87.0 million in Q1 2025.
• A 5-year average of $4.1 million and a median of -$39.5 million in 2022 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2022 — Net Cash Flow plunged 1200.46% — and 2023, when it surged 2780.59%.
• Tracing BCYC's Net Cash Flow over 5 years: stood at -$25.9 million in 2022, then slumped by 81.5% to -$47.0 million in 2023, then surged by 79.64% to -$9.6 million in 2024, then plunged by 108.5% to -$19.9 million in 2025, then slumped by 150.42% to -$49.9 million in 2026.
• The last three Net Cash Flow figures came in at -$49.9 million (Q2 2026), -$66.7 million (Q1 2026), and -$19.9 million (Q4 2025), per Business Quant data.